Trial Profile
A pilot study exploring high-dose lenalidomide maintenance therapy in adult acute myeloid leukaemia (AML).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 01 May 2019 Status changed from active, no longer recruiting to completed.
- 13 Aug 2018 Planned End Date changed from 17 Apr 2018 to 14 Apr 2019.
- 18 May 2017 Status changed from recruiting to active, no longer recruiting.